【スルリム】広告でよく見かけるあの薬は本当に効果があるのか...。【医師が解説】

🔻Discount coupons for Manjaro and other products available now! 🔻Dr. Kiya's free diet benefits are available on our official LINE account. https://swiy.co/oc_yt-to-line 🎁Free diet benefits available now!🎁 🔸Recommended for: ・Seriously wanting to lose weight and become more beautiful. ・Always gaining weight back even after dieting. ・Wanting a safe diet under medical supervision. ・Interested in popular medical diet drugs (Manjaro, GLP-1, etc.). ⭐️Channel Content ・A practicing doctor explains the benefits and risks of diet drugs like Manjaro. ・Key points for successful medical dieting based on the experience of treating over 10,000 patients. ・Tips for diet management and preventing weight gain. ・Inside the world of medical dieting and the latest trends. ◆━━━━━━━━━━━━━━━━━━━◆ ◼︎Dr. Kiya's Profile Takahiro Kiya Director of One Clinic Ebisu Representative Director of Ikakukai General Incorporated Association Dr. Kiya began his career as a physician in 2016. He offers a wide range of services, from internal medicine and COVID-19 testing to cosmetic medicine (such as hair removal). He opened One Clinic Ebisu in 2021. He has personally used Manjaro and Rebelsus, and based on his experience, he provides online consultations focusing on medical diets. ● Qualifications ・Medical License ・Occupational Health Consultant ◆━━━━━━━━━━━━━━━━━━◆ [About Treatment] (Important Information) 1. About Treatment and Prescriptions at Our Hospital At our hospital, we may prescribe type 2 diabetes medications (GLP-1 receptor agonists, SGLT2 inhibitors, metformin, etc.) as elective treatment (for obesity treatment) at the discretion of our physicians. These medications are not approved for obesity treatment in Japan, so they are used off-label. Prescription is not available for all patients, and a comprehensive assessment is required based on the patient's medical history, test results, and medical history. 2. Primary Purpose and Indications of Treatment All medications are approved for blood glucose control in type 2 diabetes. Use for obesity treatment is based on domestic and international approval status and academic guidelines, and is carried out with sufficient explanation and consent. 3. Individual Differences in Effectiveness, Side Effects, and Risks Ingestion or injection does not necessarily result in consistent weight loss. Effectiveness varies greatly from person to person, and treatment should be combined with lifestyle changes, dietary therapy, and exercise therapy. Side effects such as hypoglycemia and gastrointestinal symptoms may occur. Consult a doctor immediately if you feel unwell. 4. Possible Testing and Additional Treatment Regular testing (blood and urine tests, etc.) may be required to continue treatment. Additional consultation fees, testing fees, and additional medication costs may apply. 5. Notes Regarding Eligible Medical Treatment Prescriptions for obesity treatment are not covered by health insurance (full self-payment). Because this is off-label use, it may not be covered by the national drug adverse reaction relief system. 6. Comparison with Other Treatments and Guarantees This treatment is merely one option and is not guaranteed to be superior to other medical institutions or other treatments. Treatment effectiveness and risk of side effects vary from person to person, and expected results may not necessarily be achieved. ────────────────── ◼ GLP-1 Receptor Agonist (Oral: Rybelsus) [Treatment Details] Rybelsus is an oral GLP-1 receptor agonist used to treat blood sugar control in type 2 diabetes. At our hospital, at the physician's discretion, it may be prescribed for obesity treatment (off-label use). Its appetite suppressant effect and prolonged feeling of fullness are expected to promote weight loss. [Dosage and Administration] Take once daily before breakfast with up to 120 mL of water. Avoid eating, drinking, drinking water, or taking other medications for 30 minutes after taking this medication (to maximize its effectiveness). The initial dosage is 3 mg, increased to 7 mg after one month, and can then be increased to 14 mg as needed. [Standard Cost] Ribelsus 3mg 30-day supply: ¥9,180 7mg 30-day supply: ¥17,420 14mg 30-day supply: ¥25,650 [Major Risks/Side Effects] Gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), loss of appetite, acute pancreatitis (very rare) [Regarding the Use of Unapproved Drugs] Ribelsus is approved by the Ministry of Health, Labour and Welfare as a treatment for type 2 diabetes, but is not approved for prescription in Japan for the treatment of obesity. [Source of Acquisition] This drug is purchased from an authorized domestic distributor (pharmaceutical wholesaler). [Availability of Approved Drugs in Japan] Ugobi (injectable), which contains the same ingredients as Ribelsus, is approved in Japan for the treatment of obesity. [Safety Information in Other Countries] An injectable formulation containing the same ingredients has been approved...